Eli Lilly Tidigare resultatutveckling
Tidigare kriterier kontrolleras 5/6
Eli Lilly har ökat intäkterna med en genomsnittlig årlig takt på 35.4%, medan Pharmaceuticals -branschen såg intäkterna växer på 12.6% årligen. Intäkterna har varit växande med en genomsnittlig takt på 22.9% per år. Eli Lilly s avkastning på eget kapital är 78.8% och den har en nettomarginal på 33.5%.
Viktig information
35.35%
Tillväxttakt i vinsten
35.60%
Tillväxttakt för EPS
| Pharmaceuticals Tillväxt i branschen | 5.95% |
| Intäkternas tillväxttakt | 22.87% |
| Avkastning på eget kapital | 78.84% |
| Nettomarginal | 33.53% |
| Nästa resultatuppdatering | 29 Oct 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Seeking Alpha • Sep 05
Eli Lilly Stock Is Not Done Growing Yet, But It's Due For Compression (Rating Downgrade)
Summary Eli Lilly remains attractive versus overextended semiconductor stocks, offering a compelling short-term entry point within healthcare's more favorable valuation landscape. LLY's forward P/E of 31.5 is high, but its PEG ratio of 1.49 suggests growth justifies the premium relative to sector peers. Healthcare, led by LLY, can benefit from rotation out of crowded tech but remains correlated to broader equity sentiment and vulnerable in a market-wide selloff. LLY's Q2 revenue surged 48% on Mounjaro and Zepbound, positioning it to potentially outperform semiconductors, though not immune to systemic risk. Read the full article on Seeking Alpha
Uppdatering av berättelse • Sep 05
LLY: Incretin Obesity Franchise And Pipeline Will Support Premium Positioning Beyond 2030
The analyst fair value estimate for Eli Lilly has been raised from $1,500 to $1,600 as analysts point to strong Q2 incretin volume, obesity drug demand, and upgraded multi-year guidance as key supports for higher long-term assumptions. Analyst Commentary Recent Street research on Eli Lilly points to a broadly constructive tone, with many bullish analysts lifting price targets after Q2 results and updated guidance.
Ny berättelse • Sep 03
Eli Lilly — Leader of the GLP-1 Revolution, but Priced for Success
Eli Lilly is the leader of the obesity/diabetes revolution (GLP-1 drugs like tirzepatide), addressing one of the largest addressable markets in medical history. It's my highest-quality healthcare growth bet.
Uppdatering av berättelse • Aug 22
LLY: Obesity Franchise Concentration And Pricing Pressure Will Constrain Future Upside
Analysts have lifted the Eli Lilly fair value estimate from $899.73 to $982.09. Higher price targets reflect confidence that strong incretin demand, obesity franchise momentum and updated long-term guidance support a slightly higher assumed future P/E and profit margin, even with a modestly higher discount rate and tempered revenue growth inputs.Analysartikel • Aug 08
Eli Lilly and Company Just Beat Revenue By 11%: Here's What Analysts Think Will Happen Next
Eli Lilly and Company ( NYSE:LLY ) just released its quarterly report and things are looking bullish. It was a positive...
Uppdatering av berättelse • Aug 08
LLY: GLP-1 Leadership And Retatrutide Progress Will Drive Balanced Outlook
Analysts have increased their fair value estimate for Eli Lilly stock from $1,270.37 to $1,297.31, reflecting higher Street price targets supported by strong Q2 incretin demand, GLP-1 franchise momentum, and updated long-term modeling around obesity and diabetes therapies. Analyst Commentary Recent Street research on Eli Lilly shows a clear focus on the company’s incretin and GLP-1 portfolio, with multiple firms adjusting price targets following Q2 results, obesity and diabetes trial updates, and refreshed long term models.Uppdatering av berättelse • Jul 25
LLY: GLP-1 Leadership And Retatrutide Data Will Shape Balanced Outlook
Eli Lilly's updated fair value estimate of $1,270.37, up from $1,243.43, reflects analysts' higher price targets that lean on expectations for stronger obesity and diabetes franchise contributions, incremental support from retatrutide data, and Q2 previews that factor in relatively higher revenue growth assumptions alongside slightly adjusted long term profit margins and future P/E multiples. Analyst Commentary Recent research on Eli Lilly points to a generally constructive stance from Wall Street, with multiple firms lifting price targets as they reassess the company's obesity and diabetes portfolio, retatrutide data, and Q2 earnings setup.Uppdatering av berättelse • Jul 10
LLY: GLP-1 Franchise And Retatrutide Data Will Support Balanced Future Outlook
Analysts have nudged their price targets on Eli Lilly higher, with fair value estimates moving from about $1,218.72 to roughly $1,243.43 as they point to resilient GLP-1 obesity and diabetes franchises, along with supportive recent data and previews around Zepbound, Mounjaro, Foundayo and retatrutide. Analyst Commentary Recent research updates on Eli Lilly show a cluster of higher price targets around the GLP-1 obesity and diabetes portfolio, with Zepbound, Mounjaro, Foundayo and retatrutide at the center of the discussion.Uppdatering av berättelse • Jun 24
LLY: Retatrutide Efficacy And GLP-1 Demand Will Support Balanced Outlook
Analysts have nudged up Eli Lilly's fair value estimate by about $4 to $1,218.72, reflecting modestly higher modeled revenue growth and a slightly richer future P/E multiple, supported by recent price target increases tied to retatrutide data and broader GLP-1 expectations. Analyst Commentary Recent commentary on Eli Lilly centers on how retatrutide data and GLP-1 demand expectations filter into valuation, growth assumptions, and execution risk.Uppdatering av berättelse • Jun 09
LLY: GLP-1 Leadership And Retatrutide Data Will Support Balanced Long-Term Outlook
Analysts have inched up their price targets on Eli Lilly, with several moving into the $1,250 to $1,350 range. They cite full Phase 3 retatrutide data that showed strong obesity and Type 2 diabetes outcomes, with what they view as manageable safety trade offs and a GLP-1 profile they say will be hard for rivals to match.Uppdatering av berättelse • May 26
LLY: GLP-1 Obesity Franchise Leadership Will Drive Long-Term Profitability
Analysts have nudged their price targets on Eli Lilly higher, with our fair value estimate moving by about $2 to $1,211 per share as they factor in expectations for stronger long-term profitability and GLP-1 leadership following positive retatrutide Phase 3 data, partly offset by more tempered revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent research on Eli Lilly clusters around the same theme, retatrutide Phase 3 data supporting a premium valuation for the GLP-1 franchise, but with growing debate over how much future growth is already reflected in the stock.Uppdatering av berättelse • May 07
LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics
Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.Uppdatering av berättelse • Apr 20
LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030
Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.Uppdatering av berättelse • Apr 06
LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside
Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.Ny berättelse • Mar 25
Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth
Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).Uppdatering av berättelse • Mar 23
LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning
Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.Uppdatering av berättelse • Mar 09
LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning
The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.Uppdatering av berättelse • Feb 23
LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside
Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Eli Lilly tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 30 Jun 26 | 79,666 | 26,711 | 12,237 | 14,596 |
| 31 Mar 26 | 72,249 | 25,277 | 11,560 | 14,113 |
| 31 Dec 25 | 65,179 | 20,640 | 11,094 | 13,337 |
| 30 Sep 25 | 59,420 | 18,412 | 10,618 | 12,559 |
| 30 Jun 25 | 53,258 | 13,800 | 9,976 | 11,827 |
| 31 Mar 25 | 49,004 | 11,106 | 9,226 | 11,202 |
| 31 Dec 24 | 45,043 | 10,590 | 8,594 | 10,991 |
| 30 Sep 24 | 40,863 | 8,370 | 7,633 | 10,531 |
| 30 Jun 24 | 38,923 | 7,342 | 7,337 | 10,206 |
| 31 Mar 24 | 35,932 | 6,138 | 7,144 | 9,851 |
| 31 Dec 23 | 34,124 | 5,240 | 7,404 | 9,313 |
| 30 Sep 23 | 32,073 | 4,988 | 6,682 | 8,747 |
| 30 Jun 23 | 29,516 | 6,498 | 6,515 | 8,140 |
| 31 Mar 23 | 27,691 | 5,687 | 6,236 | 7,566 |
| 31 Dec 22 | 28,541 | 6,245 | 6,068 | 7,191 |
| 30 Sep 22 | 29,240 | 6,033 | 6,037 | 7,093 |
| 30 Jun 22 | 29,071 | 5,692 | 6,020 | 6,996 |
| 31 Mar 22 | 29,323 | 6,129 | 6,104 | 6,869 |
| 31 Dec 21 | 28,318 | 5,582 | 6,142 | 6,931 |
| 30 Sep 21 | 27,759 | 5,972 | 6,119 | 6,870 |
| 30 Jun 21 | 26,726 | 6,071 | 6,069 | 6,631 |
| 31 Mar 21 | 25,486 | 6,093 | 5,867 | 6,366 |
| 31 Dec 20 | 24,540 | 6,194 | 5,869 | 5,976 |
| 30 Sep 20 | 23,214 | 5,573 | 6,019 | 5,829 |
| 30 Jun 20 | 22,950 | 5,618 | 5,924 | 5,745 |
| 31 Mar 20 | 23,087 | 5,533 | 6,048 | 5,757 |
| 31 Dec 19 | 22,320 | 4,638 | 6,004 | 5,595 |
| 30 Sep 19 | 21,843 | 4,264 | 5,984 | 5,405 |
| 30 Jun 19 | 21,673 | 4,103 | 6,019 | 5,305 |
| 31 Mar 19 | 21,622 | 2,545 | 5,913 | 5,174 |
| 31 Dec 18 | 21,493 | 3,151 | 5,735 | 5,051 |
| 30 Sep 18 | 22,016 | 372 | 5,855 | 5,146 |
| 30 Jun 18 | 22,368 | -166 | 5,975 | 5,205 |
| 31 Mar 18 | 22,607 | 1,074 | 6,210 | 5,207 |
| 31 Dec 17 | 19,974 | -86 | 5,733 | 5,096 |
| 30 Sep 17 | 22,471 | 2,225 | 6,475 | 5,321 |
| 30 Jun 17 | 22,005 | 2,447 | 6,526 | 5,217 |
| 31 Mar 17 | 21,585 | 2,187 | 6,483 | 5,281 |
| 31 Dec 16 | 21,222 | 2,738 | 6,330 | 5,310 |
| 30 Sep 16 | 20,837 | 2,444 | 6,460 | 5,238 |
| 30 Jun 16 | 20,605 | 2,466 | 6,471 | 5,145 |
| 31 Mar 16 | 20,179 | 2,319 | 6,483 | 4,978 |
| 31 Dec 15 | 19,959 | 2,408 | 6,533 | 4,796 |
| 30 Sep 15 | 19,704 | 2,359 | 6,535 | 4,538 |
Kvalitetsintäkter: LLY har inkomster av hög kvalitet.
Växande vinstmarginal: LLY s nuvarande netto vinstmarginaler (33.5%) är högre än förra året (25.9%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: LLY s intäkter har ökat markant med 35.4% per år under de senaste 5 åren.
Accelererande tillväxt: LLY s intäktstillväxt under det senaste året ( 93.6% ) överstiger sitt 5-åriga genomsnitt ( 35.4% per år).
Resultat vs industri: LLY vinsttillväxt under det senaste året ( 93.6% ) översteg Pharmaceuticals branschen 1%.
Avkastning på eget kapital
Hög ROE: Medan LLY s avkastning på eget kapital ( 78.84% ) är utestående, är detta mått skevt på grund av deras höga skuldnivå.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/09 22:26 |
| Aktiekurs vid dagens slut | 2026/09/09 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Eli Lilly and Company bevakas av 53 analytiker. 28 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |